-+ 0.00%
-+ 0.00%
-+ 0.00%

TG Therapeutics completes enrollment in Phase 3 subcutaneous Briumvi trial in MS

PUBT·04/15/2026 11:31:30
Listen to the news
TG Therapeutics completes enrollment in Phase 3 subcutaneous Briumvi trial in MS
  • TG Therapeutics completed enrollment in a Phase 3 trial testing subcutaneous BRIUMVI in adults with relapsing forms of multiple sclerosis.
  • Top-line results have not been presented; data are expected at year-end 2026 or in Q1 2027.
  • Study compares two subcutaneous maintenance schedules against currently marketed intravenous BRIUMVI, aiming to show similar drug exposure and comparable overall performance.
  • Program positions BRIUMVI for a potential self-administered at-home option, which could expand reach and support franchise growth if results are positive.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150730PRIMZONEFULLFEED9690131) on April 15, 2026, and is solely responsible for the information contained therein.